Amorfix, Trellis Bioscience deal

The companies partnered to discover antibodies against misfolded CD38 protein to treat hematological malignancies, including leukemia and lymphoma. Trellis will use its CellSpot discovery platform - which uses computerized microscopy to "drastically miniaturize" a multiplexed antigen binding assay capable of characterizing millions of individual antibody-producing B cells - to identify antibodies that bind to disease-specific epitopes from Amorfix. Amorfix said its ProMIS Discovery technology identifies disease-specific epitopes that are present only on diseased cells. ...